New Appointments, Upcoming Earnings Releases, Regulatory Approvals, Status Updates and Informative Resources for New Treatment Options - Research Report on Mylan, Alkermes, Salix, Ligand and Hospira
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, October 30, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Mylan, Inc. (NASDAQ: MYL), Alkermes plc (NASDAQ: ALKS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Hospira Inc. (NYSE: HSP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Mylan, Inc. Research Report
On October 17, 2013, Mylan Inc. (Mylan) announced that Jacek Glinka has been appointed as the Company's President, European business with effect from December 2, 2013. Mylan stated that prior to joining the Company, Mr. Glinka served as CEO for the Polpharma Group from 2003 to 2006 and from 2009 to 2013. During his tenure with Polpharma, Glinka led the transformation of the company from a small local player into a leading pharmaceutical company in Central and Eastern Europe, the Caucasus and Central Asia. Commenting on this appointment, Mylan CEO Heather Bresch said, "We are thrilled to welcome Jacek to Mylan. His exceptional track record leading Polpharma speaks for itself and we believe his deep experience in the region will contribute to Mylan's continued success and growth in Europe. We believe Jacek's strong leadership, strategic thinking and operational discipline will build on the solid foundation and leadership team we already have in place, and maximize the many opportunities we see ahead for our European business." The Full Research Report on Mylan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5a20_MYL]
--
Alkermes plc Research Report
On October 10, 2013, Alkermes plc (Alkermes) announced that the Company's proprietary investigational medicine - ALKS 5461, has been granted Fast Track status by the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard therapies. According to the Company, Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and address unmet medical needs. Elliot Ehrich, Chief Medical Officer of Alkermes, "We are extremely pleased to have been conferred Fast Track status for ALKS 5461 as we believe that ALKS 5461 may represent an important option for the treatment of major depressive disorder, This designation supports our position that there is a clear and compelling need for a novel mechanism for the treatment of depression." The Full Research Report on Alkermes plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e2f3_ALKS]
--
Salix Pharmaceuticals Ltd. Research Report
On October 14, 2013, Salix Pharmaceuticals Ltd. (Salix) announced that Ulcerative Colitis For Dummies, Special Edition is now available online. The book is authored by Boston Medical Center's Clinical Director in Gastroenterology, Co-Director of the Center for Digestive Disorders, and Professor of Medicine at the Boston University School of Medicine, Francis A. Farraye, M.D., and M.Sc. The Company's Brand Director, Matt Mitcho said, "We hope that Ulcerative Colitis For Dummies will empower patients to talk openly with their clinicians about their condition and potential treatment options, Informing patients about UC can further expand the dialogue by getting patients to ask the right questions, become more aware of symptoms, and make the best use of the time with their provider. The goal is to help patients better understand and manage their condition." The Full Research Report on Salix Pharmaceuticals Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/04fa_SLXP]
--
Ligand Pharmaceuticals Incorporated Research Report
On October 3, 2013, Ligand Pharmaceuticals Inc. (Ligand) reported that its partner Pfizer received U.S. Food and Drug Administration (FDA) approval for DUAVEE, towards the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause and the prevention of postmenopausal osteoporosis. According to the Company, DUAVEE is the first and only therapy to pair conjugated estrogens (CE) with an estrogen agonist/antagonist also known as a selective estrogen receptor modulator (SERM). John Higgins, President and CEO of Ligand said, "There has been a significant therapeutic need for additional safe and effective medicines to improve health and well-being for women, and we commend the DUAVEE team at Pfizer for their commitment and leadership in driving this medicine to regulatory success. We are extremely pleased by the decision by the FDA, and we look forward to the launch of DUAVEE." Under the terms of a license agreement with Pfizer, Ligand has received a $425,000 milestone payment for the approval. The Full Research Report on Ligand Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3b8d_LGND]
--
Hospira Inc. Research Report
On October 7, 2013, Hospira Inc. (Hospira) announced that it will release its Q3 2013 earnings results on November 6, 2013 before the U.S. stock market opens. The Company informed that it will host a conference call to discuss its financial results on the same day at 8:00 a.m. CT. Hospira stated that a live webcast of the conference call, its replay (accessible for 30 days) and related material will be available on the Company's website. The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1f43_HSP]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsCorner.com
SOURCE Analysts' Corner
Share this article